VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Summary
Third Opinion Trial Synopsis:
Scientists are testing a new treatment for cancer that uses a virus called VSV-hIFNbeta-NIS to kill cancer cells without harming normal cells. They want to find the best amount of the virus to use and see if it works better with other treatments like cyclophosphamide or ipilimumab and nivolumab. These other treatments may also help the body's immune system stop cancer from growing and spreading. The scientists hope this treatment will work especially well for people with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that doesn't respond to other treatments.
Scientists are testing a new treatment for cancer that uses a virus called VSV-hIFNbeta-NIS to kill cancer cells without harming normal cells. They want to find the best amount of the virus to use and see if it works better with other treatments like cyclophosphamide or ipilimumab and nivolumab. These other treatments may also help the body's immune system stop cancer from growing and spreading. The scientists hope this treatment will work especially well for people with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that doesn't respond to other treatments.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without cyclophosphamide or ipilimumab and nivolumab in treating patients with multiple myeloma, acute myeloid leukemia (AML) or lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Immunotherapy with ipilmumab and nivolumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving VSV-hIFNbeta-NIS and ruxolitinib phosphate may work better at treating multiple myeloma, acute myeloid leukemia and T-cell lymphoma.
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without cyclophosphamide or ipilimumab and nivolumab in treating patients with multiple myeloma, acute myeloid leukemia (AML) or lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Immunotherapy with ipilmumab and nivolumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving VSV-hIFNbeta-NIS and ruxolitinib phosphate may work better at treating multiple myeloma, acute myeloid leukemia and T-cell lymphoma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: